ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Recruiting now · Has a placebo group

Conditions studied: Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis

In brief

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

Key facts

Study ID

NCT07294170

Run by

argenx

People needed

70

Starts

2025-12-19

Expected to finish

2028-03-07

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is at least 18 years of age and the local legal age of consent for clinical studies
• Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment
• If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening

You may not qualify if…

• Known autoimmune disease or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk
• Is MGFA (Myasthenia Gravis Foundation of America) Class V

Where it is running

• Profound Research LLC - Carlsbad — Carlsbad, California, United States (enrolling)
• Visionary Investigators Network — Miami, Florida, United States (enrolling)
• Visionary Investigators Network — Miami, Florida, United States (enrolling)
• University of South Florida — Tampa, Florida, United States (enrolling)
• Erlanger Health System — Columbia, Maryland, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Henry Ford Health System — Detroit, Michigan, United States (enrolling)
• Dent Neurologic Institute - Amherst — Amherst, New York, United States (enrolling)
• Duke Early Phase Clinical Research Unit - PPDS — Durham, North Carolina, United States (enrolling)
• Ohio State Martha Morehouse Outpatient Care — Columbus, Ohio, United States (enrolling)
• Erlanger Health System — Chattanooga, Tennessee, United States (enrolling)
• Erlanger Neuroscience Institute — Chattanooga, Tennessee, United States (enrolling)
• National Neuromuscular Research Institute — Austin, Texas, United States (enrolling)
• University of Texas- San Antonio - Health Science Center - PPDS — San Antonio, Texas, United States (enrolling)
• UZ Leuven - PPDS — Leuven, Belgium (enrolling)
• Charité - Universitätsmedizin Berlin — Berlin, Germany (enrolling)
• Eginitio Hospital — Athens, Greece (enrolling)
• AHEPA University General Hospital of Thessaloniki — Thessaloniki, Greece (enrolling)
• ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII — Bergamo, Lombardy, Italy (enrolling)
• Fondazione IRCCS Istituto Neurologico Carlo Besta — Milan, Lombardy, Italy (enrolling)
• Fondazione IRCCS Istituto Neurologico Carlo Besta — Milan, Italy (enrolling)
• AORN Antonio Cardarelli — Naples, Italy (enrolling)
• IUHW Narita Hospital — Narita, Japan (enrolling)
• MICS Centrum Medyczne Bydgoszcz — Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland (enrolling)
• Krakowska Akademia Neurologii Sp. z o.o. — Krakow, Lesser Poland Voivodeship, Poland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.